Nigam V N, Brière N, Bonaventure J, Pageau R, Bissonnette E, Brailovsky C, Madarnas P
Anticancer Res. 1986 Mar-Apr;6(2):245-50.
Therapeutic effects of radiotherapy (R), chemotherapy, and maltose tetrapalmitate (MTP) immunotherapy alone and in combinations were tried against 4' dimethylaminoazobenzene (DAB) induced primary liver cancer in Wistar rats in three separate protocols. Rats were fed a low protein synthetic diet containing 0.06% DAB for 90-120 days. Around 90 days, liver cancers developed in all the animals. In the first protocol, animals were either left untreated or treated with cyclophosphamide (Cy), MTP (i.p. or oral) and Cy plus oral MTP. Rats in the MTP (i.p.) group maintained a steady liver weight but neither Cy nor Cy + MTP influenced the survival time or liver weight. In the second protocol, R as well as a 3-drug combination at 2 dose levels were tried alone and with MTP before or soon after cessation of DAB feeding. Survival times were decreased by R and chemotherapy due to combined toxicities of DAB and treatments and were partially restored by MTP. In the third protocol, MTP, R, and Cy were each tried alone and in combinations, 21 days after cessation of 100-day DAB feeding. Increase in survivals were obtained by each treatment, although tumor weight was best controlled by triple R+ Cy + MTP combination.
在三个独立的实验方案中，分别尝试了单独及联合使用放疗（R）、化疗和麦芽四棕榈酸酯（MTP）免疫疗法，以治疗4'-二甲基氨基偶氮苯（DAB）诱导的Wistar大鼠原发性肝癌。给大鼠喂食含0.06% DAB的低蛋白合成饮食90至120天。大约90天时，所有动物均发生肝癌。在第一个实验方案中，动物要么不接受治疗，要么接受环磷酰胺（Cy）、MTP（腹腔注射或口服）以及Cy加口服MTP治疗。MTP（腹腔注射）组的大鼠肝脏重量保持稳定，但Cy和Cy + MTP均未影响生存时间或肝脏重量。在第二个实验方案中，在停止喂食DAB之前或之后不久，单独及联合使用R以及两种剂量水平的三联药物，并与MTP联合使用。由于DAB和治疗的联合毒性，放疗和化疗使生存时间缩短，而MTP可部分恢复生存时间。在第三个实验方案中，在停止100天DAB喂食21天后，分别单独及联合使用MTP、R和Cy。每种治疗均使生存率提高，尽管肿瘤重量由三联R + Cy + MTP组合控制得最好。
